Eplerenone in Patients with Systolic Heart Failure and Mild Symptoms (Q44272913)

1 December 2017

title

Eplerenone in patients with systolic heart failure and mild symptoms (English)

1 reference

1 December 2017

Eplerenone in Patients with Systolic Heart Failure and Mild Symptoms (English)

1 reference

Crossref

DOI

https://api.crossref.org/works/10.1056/NEJMOA1009492

25 August 2024

0 references

0 references

1 reference

systolic heart failure

1 reference

Faiez Zannad

1 reference

1 December 2017

Bertram Pitt

1 reference

1 December 2017

Karl Swedberg

1 reference

1 December 2017

Henry Krum

1 reference

1 December 2017

Dirk J van Veldhuisen

object named as

Dirk J van Veldhuisen

1 reference

1 December 2017

John J V McMurray

1 reference

1 December 2017

Harry Shi

1 reference

1 December 2017

EMPHASIS-HF Study Group

object named as

EMPHASIS-HF Study Group

1 reference

1 December 2017

John Vincent

1 reference

1 December 2017

John J. V. McMurray

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A21073363

25 August 2024

Stuart J. Pocock

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A21073363

25 August 2024

language of work or name

English

0 references

publication date

14 November 2010

1 reference

full work available at URL

1 December 2017

https://doi.org/10.1056/nejmoa1009492

online access status

open access

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A21073363

http://content.nejm.org/cgi/content/abstract/364/1/11

25 August 2024

online access status

open access

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A21073363

http://www.nejm.org/doi/pdf/10.1056/NEJMoa1009492

25 August 2024

1 reference

Crossref

DOI

https://api.crossref.org/works/10.1056/NEJMOA1009492

The New England Journal of Medicine

25 August 2024

published in

1 reference

1 December 2017

volume

364

1 reference

1 December 2017

1 reference

1 December 2017

page(s)

11-21

1 reference

Reconsidering the roles of the mineralocorticoid receptor

1 December 2017

cites work

1 reference

https://api.crossref.org/works/10.1056/NEJMOA1009492

The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators

25 August 2024

1 reference

https://api.crossref.org/works/10.1056/NEJMOA1009492

Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction

25 August 2024

1 reference

https://api.crossref.org/works/10.1056/NEJMOA1009492

ESC guidelines for the diagnosis and treatment of acute and chronic heart failure 2008: the Task Force for the diagnosis and treatment of acute and chronic heart failure 2008 of the European Society of Cardiology

25 August 2024

1 reference

https://api.crossref.org/works/10.1056/NEJMOA1009492

2009 Focused update incorporated into the ACC/AHA 2005 Guidelines for the Diagnosis and Management of Heart Failure in Adults A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines Deve

25 August 2024

1 reference

https://api.crossref.org/works/10.1056/NEJMOA1009492

Rationale and design of the Eplerenone in Mild Patients Hospitalization And SurvIval Study in Heart Failure (EMPHASIS-HF).

25 August 2024

1 reference

https://api.crossref.org/works/10.1056/NEJMOA1009492

Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function taking angiotensin-converting-enzyme inhibitors: the CHARM-Added trial

25 August 2024

1 reference

https://api.crossref.org/works/10.1056/NEJMOA1009492

Calculating the number needed to treat for trials where the outcome is time to an event

25 August 2024

1 reference

https://api.crossref.org/works/10.1056/NEJMOA1009492

Aldosterone induces a vascular inflammatory phenotype in the rat heart

25 August 2024

1 reference

https://api.crossref.org/works/10.1056/NEJMOA1009492

Activation of cardiac aldosterone production in rat myocardial infarction: effect of angiotensin II receptor blockade and role in cardiac fibrosis

25 August 2024

1 reference

https://api.crossref.org/works/10.1056/NEJMOA1009492

Molecular mechanisms of myocardial remodeling. The role of aldosterone

25 August 2024

1 reference

https://api.crossref.org/works/10.1056/NEJMOA1009492

The clinical implications of aldosterone escape in congestive heart failure.

25 August 2024

1 reference

https://api.crossref.org/works/10.1056/NEJMOA1009492

Effect of beta blockade (carvedilol or metoprolol) on activation of the renin-angiotensin-aldosterone system and natriuretic peptides in chronic heart failure

25 August 2024

1 reference

https://api.crossref.org/works/10.1056/NEJMOA1009492

Comparison of candesartan, enalapril, and their combination in congestive heart failure: randomized evaluation of strategies for left ventricular dysfunction (RESOLVD) pilot study. The RESOLVD Pilot Study Investigators

25 August 2024

1 reference

https://api.crossref.org/works/10.1056/NEJMOA1009492

Anti-remodelling effect of canrenone in patients with mild chronic heart failure (AREA IN-CHF study): final results

25 August 2024

1 reference

https://api.crossref.org/works/10.1056/NEJMOA1009492

Sustained reduction of aldosterone in response to the angiotensin receptor blocker valsartan in patients with chronic heart failure: results from the Valsartan Heart Failure Trial

25 August 2024

1 reference

https://api.crossref.org/works/10.1056/NEJMOA1009492

Aldosterone and cardiac fibrosis: in vitro studies

25 August 2024

1 reference

https://api.crossref.org/works/10.1056/NEJMOA1009492

Aldosterone and spironolactone in heart failure

25 August 2024

1 reference

https://api.crossref.org/works/10.1056/NEJMOA1009492

Limitation of Excessive Extracellular Matrix Turnover May Contribute to Survival Benefit of Spironolactone Therapy in Patients With Congestive Heart Failure

25 August 2024

1 reference

https://api.crossref.org/works/10.1056/NEJMOA1009492

Immediate administration of mineralocorticoid receptor antagonist spironolactone prevents post-infarct left ventricular remodeling associated with suppression of a marker of myocardial collagen synthesis in patients with first anterior acute myocard

25 August 2024

1 reference

https://api.crossref.org/works/10.1056/NEJMOA1009492

Extracellular cardiac matrix biomarkers in patients with acute myocardial infarction complicated by left ventricular dysfunction and heart failure: insights from the Eplerenone Post-Acute Myocardial Infarction Heart Failure Efficacy and Survival Stu

25 August 2024

1 reference

https://api.crossref.org/works/10.1056/NEJMOA1009492

A propensity-matched study of the association of low serum potassium levels and mortality in chronic heart failure

25 August 2024

1 reference

https://api.crossref.org/works/10.1056/NEJMOA1009492

Effect of spironolactone on plasma brain natriuretic peptide and left ventricular remodeling in patients with congestive heart failure

25 August 2024

1 reference

https://api.crossref.org/works/10.1056/NEJMOA1009492

Implementation of device therapy (cardiac resynchronization therapy and implantable cardioverter defibrillator) for patients with heart failure in Europe: changes from 2004 to 2008.

25 August 2024

1 reference

https://api.crossref.org/works/10.1056/NEJMOA1009492

Ivabradine and outcomes in chronic heart failure (SHIFT): a randomised placebo-controlled study

25 August 2024

1 reference

https://api.crossref.org/works/10.1056/NEJMOA1009492

When (not) to stop a clinical trial for benefit.

25 August 2024

1 reference

https://api.crossref.org/works/10.1056/NEJMOA1009492

25 August 2024

Identifiers

DOI

1 reference

1 December 2017

1 reference